Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
18.60
-1.49 (-7.42%)
At close: Apr 28, 2026, 4:00 PM EDT
18.25
-0.35 (-1.88%)
After-hours: Apr 28, 2026, 4:20 PM EDT
Aktis Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aktis Oncology stock have an average target of 31.5, with a low estimate of 30 and a high estimate of 33. The average target predicts an increase of 69.35% from the current stock price of 18.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aktis Oncology stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 0 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 1 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $33 | Strong Buy | Maintains | $30 → $33 | +77.42% | Mar 31, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +61.29% | Mar 9, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $30 | Buy | Initiates | $30 | +61.29% | Feb 3, 2026 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $2 → $1 | Buy → Hold | Downgrades | $2 → $1 | -94.62% | Jan 4, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $6 → $3 | Buy | Maintains | $6 → $3 | -83.87% | Sep 7, 2023 |
Financial Forecast
Revenue This Year
20.09M
from 6.50M
Increased by 209.28%
Revenue Next Year
22.20M
from 20.09M
Increased by 10.49%
EPS This Year
-1.66
from -78.34
EPS Next Year
-1.63
from -1.66
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 52.5M | 42.0M |
| Avg | 20.1M | 22.2M |
| Low | n/a | 6.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 708.1% | 109.0% |
| Avg | 209.3% | 10.5% |
| Low | - | -65.9% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -0.84 | -1.10 |
| Avg | -1.66 | -1.63 |
| Low | -2.89 | -2.30 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.